Interventions of interest:

  • fluticasone furoate and vilanterol (Breo Ellipta®, GSK)
  • fluticasone furoate, vilanterol, and umeclidinium (Trelegy Ellipta®, GSK)

ICER will develop a special report for CMS on two therapies in high demand for treating chronic obstructive pulmonary disease (COPD). This report will be submitted to CMS as part of the 2025 public comment process defined in CMS guidance on Medicare Drug Price Negotiations for price applicability year 2027. 

Date of publication: March 2025

For more information please contact Becca Piltch, Program Manager, at bpiltch@icer.org.